Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesityCompleted $238.3 million initial public offering and ...

BioAge Labs (BIOA) announced that it will present new preclinical data for its lead product candidate azelaprag, an orally available small ...

Not only are deals going off at higher valuations than the companies initially anticipated, but the prices have been popping after the stocks began trading in the public markets. Observers are hoping ...

Septerna's protracted initial public offering (IPO) on the Nasdaq has finally reached its conclusion, with the final amount ...

Follow us on Facebook and join our Telegram channel for the latest updates. A chef made famous by a hit Netflix show is poised to boost South Korea’s struggling IPO market, listing his restaurant ...

Septerna now offering 16 mln shares vs 15.3 mln shares earlier Sets IPO price at $18 a share Drug developer backed by Goldman, Third Rock Ventures Listing follows a spate of biotech IPOs since ...

Drug developers have achieved resounding success in the fall U.S. IPO market, with all the $100-million plus offerings since September upsized. Robust debuts by drug developers Bicara Therapeutics , ...

Septerna, in which Goldman owns a 5.4% stake, now aims to raise $275 million by selling nearly 15.3 million shares priced at $18 apiece. Drug developers have achieved resounding success in the fall U.

Waaree Energies IPO: The initial public offering (IPO) of the solar PV module manufacturer Waaree Energies Limited was subscribed over 76 times on the third and last day of the issue. Notably ...

Goldman Sachs initiated coverage of BioAge Labs (BIOA) with a Not Rated. The firm models for peak azelaprag sales of $8.5B in ...